Sugi Predict

Sugi Predict / Compounds / SCHEMBL3348374

SCHEMBL3348374

SCHEMBL3348374

O=c1[nH]c2ccc(I)cc2[nH]1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 3/20 0.48
▸ PKM P14618 1/20 0.48
▸ PDE3B Q13370 2/20 0.48
▸ PDE3A Q14432 2/20 0.48
▸ GRIA1 P42261 4/20 0.44
▸ CACNG8 Q8WXS5 4/20 0.44
▸ KDM4E B2RXH2 2/20 0.41
▸ GRIN2D O15399 1/20 0.40
▸ GRIN3B O60391 1/20 0.40
▸ GRIN1 Q05586 1/20 0.40
▸ GRIN2A Q12879 1/20 0.40
▸ GRIN2B Q13224 1/20 0.40
▸ GRIN2C Q14957 1/20 0.40
▸ GRIN3A Q8TCU5 1/20 0.40
▸ ALDH1A1 P00352 3/20 0.40
▸ MAPT P10636 3/20 0.40
▸ ATM Q13315 1/20 0.40
▸ PTK6 Q13882 1/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4707702 0.86 GRIN2D (0.56) GRIA1KDM4EGRIN2DGRIN3BGRIN1
SCHEMBL3666779 0.79 CA12 (0.54) PDE3BPDE3AKDM4EALDH1A1
SCHEMBL4174954 0.79 PARP1 (0.53) PDE3BPDE3AKDM4EALDH1A1
SCHEMBL1048084 0.71 GAA (0.48) GAAPKMPDE3BPDE3AGRIA1
SCHEMBL92048 0.71 GAA (0.53) GAAPKMPDE3BPDE3AGRIA1
SCHEMBL318595 0.71 GRIN2D (0.75) GAAPKMPDE3BPDE3AGRIA1
SCHEMBL3226331 0.71 PDE3B (0.50) GAAPKMPDE3BPDE3AGRIA1
SCHEMBL13293335 0.71 GAA (0.48) GAAPKMPDE3BPDE3AGRIA1
SCHEMBL18072323 0.71 GAA (0.48) GAAPKMPDE3BPDE3AGRIA1
SCHEMBL29798542 0.71 KDM4E (0.75) GAAPKMPDE3BPDE3AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118206529-A Dihydrobenzimidazolone C4医药公司 2024-06-18 — — CN disclosed
US-20240109889-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2024-04-04 — — US disclosed
WO-2024050825-A1 COMPOUNDS AS MLKL INHIBITORS NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2024-03-14 — — WO disclosed
WO-2024050825-A1 COMPOUNDS AS MLKL INHIBITORS NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2024-03-14 — — WO disclosed
CN-111315735-B Dihydrobenzimidazolone C4医药公司 2024-03-08 — — CN disclosed
US-11787802-B2 Dihydrobenzimidazolones for medical treatment C4 THERAPEUTICS, INC. (US) 2023-10-17 — — US disclosed
US-11666577-B2 MLKL inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2023-06-06 — — US disclosed
US-11666577-B2 MLKL inhibitors NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) 2023-06-06 — — US disclosed
CN-110573509-B MLKL inhibitors 北京生命科学研究所 2023-05-26 — — CN disclosed
US-20220289738-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2022-09-15 — — US disclosed
US-20030036652-A1 Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4'-piperidines NEUROGEN CORPORATION 2003-02-20 — — US disclosed
US-6509464-B1 1-Heteroaryl-pyrrolidine, piperidine, or homopiperidine derivates; nervous system disorder treatment; amidation PFIZER INC 2003-01-21 — — US disclosed
US-6498275-B1 Use of compounds for the elevation of pyruvate dehydrogenase activity ASTRAZENECA AB (SE) 2002-12-24 — — US disclosed
US-6495549-B1 1-HETEROARYL-PIPERIDINE DERIVATIVES; MODERATING NEURONAL DEGENERATION; PROMOTING NEURONAL REGENERATION AND OUTGROWTH; TREATOG NEUROLOGICAL DISORDERS ARISING FROM NEURODEGENERATIVE DISEASES OR OTHER DISORDERS INVOLVING NERVE DAMAGE PFIZER INC 2002-12-17 — — US disclosed
EP-1098894-B1 FKBP INHIBITORS PFIZER LTD (GB) 2002-10-02 — — EP disclosed
EP-1098894-A1 FKBP INHIBITORS Pfizer Limited (GB) 2001-05-16 — — EP disclosed
EP-1082110-A1 USE OF COMPOUNDS FOR THE ELEVATION OF PYRUVATE DEHYDROGENASE ACTIVITY AstraZeneca AB (SE) 2001-03-14 — — EP disclosed
US-6166011-A FKBP inhibitors PFIZER INC (US) 2000-12-26 — — US disclosed
WO-2000005231-A1 FKBP INHIBITORS PFIZER LIMITED (GB) 2000-02-03 — — WO disclosed
WO-1999062506-A1 USE OF COMPOUNDS FOR THE ELEVATION OF PYRUVATE DEHYDROGENASE ACTIVITY ASTRAZENECA AB (SE) 1999-12-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109889-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT CRBN, CUL4A, ADRM1 GAA 1982/4885PKM 3153/4885PDE3B 4080/4885
US-20220289738-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT CRBN, CUL4A, ADRM1 GAA 1982/4885PKM 3153/4885PDE3B 4080/4885
US-20030036652-A1 Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4'-piperidines NPY5R, NPY4R, NPY1R GAA 1216/4885PKM 1985/4885PDE3B 819/4885
US-11666577-B2 MLKL inhibitors MLKL, CMKLR1, PCSK9 GAA 590/4885PKM 2309/4885PDE3B 1435/4885
US-11787802-B2 Dihydrobenzimidazolones for medical treatment CRBN, CUL4A, ADRM1 GAA 1982/4885PKM 3153/4885PDE3B 4080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.